Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21418964 | 0.89 | HRH3 (0.31) | HRH3 | |
| SCHEMBL19629542 | 0.89 | HRH3 (0.31) | HRH3 | |
| SCHEMBL24941788 | 0.83 | HRH3 (0.35) | HRH3CYP2D6 | |
| SCHEMBL14725160 | 0.82 | HRH3 (0.36) | HRH3CYP2D6NAMPT | |
| SCHEMBL19506672 | 0.82 | NAMPT (0.30) | NAMPT | |
| SCHEMBL24437680 | 0.81 | HRH3 (0.34) | HRH3CYP2D6 | |
| SCHEMBL20661571 | 0.81 | HRH3 (0.38) | HRH3CYP2D6NAMPT | |
| SCHEMBL20350385 | 0.80 | HRH3 (0.34) | HRH3 | |
| SCHEMBL26049289 | 0.80 | HRH3 (0.32) | HRH3 | |
| SCHEMBL25089131 | 0.79 | HRH3 (0.33) | HRH3CYP2D6NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230061736-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220153719-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2022-05-19 | — | — | US | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | HRH3 297/4885CYP2D6 255/4885NAMPT 2863/4885 |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | HRH3 297/4885CYP2D6 255/4885NAMPT 2863/4885 |
| US-20230061736-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | HRH3 1108/4885CYP2D6 2317/4885NAMPT 1084/4885 |
| US-20220153719-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | HRH3 1108/4885CYP2D6 2317/4885NAMPT 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.